PET imaging of proliferation with pyrimidines

Journal of Nuclear Medicine

Volumn 54, Issue 6, 2013, Pages 903-912

  Tehrani, Omid S ^a   Shields, Anthony F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FLT; PET; Proliferation; Thymidine

Indexed keywords

3' FLUOROTHYMIDINE; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; PREDNISONE; PYRIMIDINE; RITUXIMAB; THYMIDINE; THYMIDINE KINASE 1; TRACER; VINCRISTINE;

B CELL LYMPHOMA; BRAIN TUMOR; BREAST CANCER; BREAST TUMOR; CANCER RADIOTHERAPY; CELL DIVISION; CELL PROLIFERATION; CELL TRANSPORT; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM CANCER; DNA SYNTHESIS; GLIOMA; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN CANCER; TREATMENT RESPONSE; TUMOR GROWTH; UROGENITAL TRACT CANCER;

FLT; PET; PROLIFERATION; THYMIDINE;

ANIMALS; CELL PROLIFERATION; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES;

EID: 84878655753     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.112201     Document Type: Review

References (83)

1. Pitter KL, Galban CJ, Galban S, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS ONE. 2011;6:e14545.
2. Ross BD, Zhao YJ, Neal ER, et al. Contributions of cell kill and post-treatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MR imaging study. Proc Natl Acad Sci USA. 1998;95:7012-7017. (Pubitemid 28278098)
3. Perumal M, Pillai RG, Barthel H, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 2006;66:8558-8564. (Pubitemid 44449169)
4. 3H-FMAU in proliferating and non-proliferating human tumor cells. J Nucl Med. 2010;51:1464-1471.
5. Mankoff DA, Shields AF, Lee TT, Graham MM. Tracer kinetic model for quantitative imaging of thymidine utilization using [C-11]thymidine and PET [abstract]. J Nucl Med. 1994;35(suppl):138P.
6. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281-287.
7. 18F- fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2012;48:3499-3513.
8. Tehrani OS, Douglas KA, Lawhorn-Crews JM, Shields AF. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. Eur J Nucl Med Mol Imaging. 2008;35:1480-1488.
9. Shields AF. PET imaging of tumor growth: not as easy as it looks. Clin Cancer Res. 2012;18:1189-1191.
10. 18F]FLT-PET imaging does not always "light up" proliferating tumor cells. Clin Cancer Res. 2012;18:1303-1312.
11. Shields AF, Grierson J, Dohmen B, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336. (Pubitemid 28512118)
12. 18F-FLT PET scanning. Bone Marrow Transplant. 2011;46:110-115.
13. Agool A, Slart RH, Kluin PM, de Wolf JT, Dierckx RA, Vellenga E. F-18 FLT PET: a noninvasive diagnostic tool for visualization of the bone marrow compartment in patients with aplastic anemia: a pilot study. Clin Nucl Med. 2011;36:286-289.
14. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med. 2006;47:1592-1598.
15. 18F]fluorothymidine PET quantification of bone marrow response to radiation dose. Int J Radiat Oncol Biol Phys. 2011;81:888-893.
16. McGuire SM, Menda Y, Ponto LL, Gross B, Juweid M, Bayouth JE. A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. Radiother Oncol. 2011;99:49-54.
17. 18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol. 2010;37:433-438.
18. 18F-fluorodeoxythymidine. J Nucl Med. 2008;49:1756-1762.
19. 18F]fluorothymidine PET imaging in the diagnosis of leptomeningeal involvement with diffuse large B-cell lymphoma. Cancer Imaging. 2011;11:140-143.
20. 18F]FLT PET imaging. Leuk Res. 2011;35:310-316.
21. Hussein K, Jahagirdar B, Gupta P, Burns L, Larsen K, Weisdorf D. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia. Am J Hematol. 2008;83:446-450. (Pubitemid 351742790)
22. 18F-fluorothymidine PET for initial and early response imaging in mantle cell lymphoma. J Nucl Med. 2011;52:1898-1902.
23. 18F-FLT positron emission tomography/computed tomography in diagnosis and staging of diffuse large B-cell lymphoma. J Exp Hematol. 2012;20:603-607.
24. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-3558.
25. 18F]fluorodeoxythymidine. Clin Cancer Res. 2008;14:2970-2977.
26. 18F-3′-fluoro- 3′-deoxy-L-thymidine. Clin Cancer Res. 2004;10:1685-1690.
27. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med. 2007;48:367-372.
28. 18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer. 2012;118:3135-3144.
29. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004;31:720-724.
30. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-1347. (Pubitemid 47312585)
31. 18F]fluorothymidine uptake measures for monitoring response to chemotherapy in locally advanced breast cancer. Mol Imaging Biol. 2012;14:777-782.
32. Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T. Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas. J Biomed Biotechnol. 2012;2012:205818.
33. 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med. 2012;37:854-861.
34. 18F-fluorothymidine PET and MR imaging for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012;53:29-36.
35. 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro-Oncol. 2012;14:1079-1089.
36. Saga T, Kawashima H, Araki N, et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med. 2006;31:774-780. (Pubitemid 44789556)
37. 18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol. 2009;11:343-355.
38. 18F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res. 2011;17:6553-6562.
39. 18F]fluorothymidine positron emission tomography in recurrent brain tumor. J Comput Assist Tomogr. 2011;35:679-684.
40. 18F-FDG PET. Nucl Med Commun. 2009;30:841-845.
41. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut. 2003;52:1602-1606. (Pubitemid 37363445)
42. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging. 2003;30:988-994.
43. 18F]-3′-deoxy- 3′fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol. 2013;15:106-113.
44. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study. Dis Esophagus. 2012;25:416-426.
45. 18F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys. 2010;76:1235-1241.
46. 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med. 2005;46:1321-1325.
47. 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med. 2010;51:528-534.
48. 18F-FDG: a comparative analysis. J Nucl Med. 2007;48:1945-1950.
49. 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2009;36:382-388.
50. Ott K, Herrmann K, Schuster T, et al. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol. 2011;18:3316-3323.
51. 18F-FLT uptake with equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in gastrointestinal cancer. Nucl Med Commun. 2011;32:460-465.
52. 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours. Nucl Med Commun. 2011;32:91-97.
53. 18F-fluorothymidine. J Nucl Med. 2009;50:1441-1447.
54. 18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging. 2012;39:846-851.
55. Herrmann K, Eckel F, Schmidt S, et al. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. J Nucl Med. 2008;49:1437-1444.
56. 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur J Nucl Med Mol Imaging. 2008;35:527-531.
57. Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med. 2006;31:788-789. (Pubitemid 44789558)
58. Liu G, Jeraj R, Vanderhoek M, et al. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res. 2011;17:7634-7644.
59. 18F] 3′deoxy-3- fluorothymidine positron emission tomography/computed tomography imaging. Nucl Med Biol. 2011;38:485-491.
60. 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med. 2010;51:845-853.
61. 3 integrin expression could [letter]. J Nucl Med. 2011;52:840.
62. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-735.
63. 18F-FDG PET for detection of cervical lymph node metastases in head and neck cancers. Acta Otolaryngol. 2012;132:1347-1354.
64. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med. 2010;51:866-874.
65. 18F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin. 2008;47:80-85.
66. 18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med. 2012;53:1521-1527.
67. 18F-FLT PET studies in lung tumors. J Nucl Med. 2011;52:1181-1188.
68. 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610-1616.
69. 18F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:1289-1296.
70. 18f-fluoro-D-glucose. J Comput Assist Tomogr. 2008;32:432-437.
71. 18F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2008;35:236-245.
72. 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129:393-401.
73. Kahraman D, Holstein A, Scheffler M, et al. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med. 2012;37:1058-1064.
74. 18F]fluorothymidine positron emission tomography. J Clin Oncol. 2011;29:1701-1708.
75. 18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer. J Nucl Med. 2012;53:443-450.
76. 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75:1098-1104.
77. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med. 2005;46:274-282. (Pubitemid 43073435)
78. 18F-FDG. J Nucl Med. 2003;44:1426-1431.
79. 18F-fluoro-3′-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med. 2003;44:1927-1932.
80. 18F]FLT) PET imaging. Proc Natl Acad Sci USA. 2011;108:18396-18399.
81. 18F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010;51:340-346.
82. 18F]-tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone. Mol Imaging Biol. 2009;11:308-321.
83. Katz SI, Zhou L, Ferrara TA, et al. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. Int J Oncol. 2011;39:91-100.